Podcasts about halozyme

Watch on YouTube In this investing masterclass, John Rosier - ex fund manager, professional investor & author of John's Investment Chronicle - takes me through his view of the markets and latest thoughts on 18 companies, including: 00:00 What type of stocks John prefers. 02:50 Bonkers stocks - Polar Capital 07:40 Portfolio performance & tweaking investment tactics 09:30 WHSmith & using stop losses 14:40 Equity outlook 21:10 Serica Energy plc 25:50Premier Foods 30:00 ME Group 33:15 PayPoint 36:30 Bloomsbury Publishing 41:05 Plus500 44:35 IG Group 45:45 NIOX 48:30 Halozyme, Inc. 51:35 Bioventix 53:10 Renew Holdings 58:10 Zegona Communications 62:15 Gamma Communications 66:50 Pollen Street Capital 69:45 Intermediate Capital Group 71:20 XPS Pensions 73:40 3 favourite ideas for 2025.

On this episode, Brad Loncar, Sam Fazeli, Tess Cameron, Nina Kjellson and Michal Preminger kick off the show sharing perspectives on Trump's selection of Robert F. Kennedy Jr as secretary of the U.S. Department of Health and Human Services. The hosts shift to Abbvie's disappointing Phase 2 trials and a broader discussion on why M&A can be tough. The group also discussed the recent flood of licensing and new companies based on China assets, including some of the players and approaches. The hosts also discuss Halozyme's takeover proposal of Evotec, the VEGF/PD-1 frenzy, J&J hits back with 340b lawsuit, the GOP tax bill and impact on biopharma priorities, and more. This episode aired on November 15, 2024.

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — FDA grants Regenxbio accelerated approval pathway for Duchenne gene therapy The bad —  Neurogene reports patient death in Rett syndrome gene therapy trial The ugly —  Halozyme withdraws acquisition proposal for Evotec

US futures are pointing to a lower open today. European equity markets have opened in the negative territory, following mixed Asian markets in a directionless Friday session. Markets are increasingly choppy with focus turning to fiscal backdrop and monetary policy outlook. Fed officials more cautious. ECB seemed ready to ease again in December. BOE remarks on hawkish side.Companies Mentioned: Citigroup, Halozyme, Evotec

Alissa Coram and Ken Shreve discuss technical action and stocks to watch in the stock market today.

Helen Torley, CEO of Halozyme Therapeutics, shares her thoughts with BioBoss host John Simboli about leadership in biopharma and how Halozyme is working to reinvent the patient experience by easing the burden of treatment and improving patient outcomes.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoyce O'Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerSara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoyce O'Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerSara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoyce O'Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerSara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoyce O'Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerSara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

The FDA Group's CEO, Nick Capman, sits down with Steve Knowles, MB.BS, M.R.C.P., M.F.P.M., Chief Medical Officer at Halozyme, a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. They discuss advancements in drug delivery technology and the role of leadership in fostering innovation and addressing challenges in this field. Discussion points include: » Dr. Knowles's transition from a physician in the UK to Chief Medical Officer at Halozyme in San Diego. » The evolution in drug delivery systems, such as the shift from hospital-based treatments to self-administration of drugs at home and the introduction of auto-injectors and on-body devices for efficient, patient-friendly drug administration. » Addressing human factors and compliance to ensure products are user-friendly—and the importance of human factor studies in product development. » The advantages of subcutaneous drug delivery, including reduced side effects, improved pharmacokinetic profiles, and patient convenience. » How Halozyme's one-team approach fosters a culture of curiosity, flexibility, and feedback. » Aligning individual and organizational goals to drive innovation. Dr. Knowles has deep pharmacovigilance and medical affairs experience gained over a career spanning almost 20 years. Dr. Knowles joined Halozyme in January 2018 as Vice President, Drug Safety & Pharmacovigilance. He is responsible for the Medical, Regulatory and Drug Safety organizations. Prior to Halozyme, Dr. Knowles served as Senior Medical Director, Global Patient Safety and Benefit Risk Management at Eli Lilly & Co. where he led the global safety physician/scientist group responsible for overseeing the safety profiles and benefit risk management of medicines across all therapeutic areas and phases of development and supported numerous BLA and MAA submissions. During his 16 years at Lilly, he held positions in Medical Affairs and from 2005 to 2017 he held roles of increasing responsibility within Global Patient Safety. Prior to these roles, Dr. Knowles spent more than 17 years in clinical practice in the UK in both hospital-based and general practice roles. Dr. Knowles received his Bachelor of Medicine and Surgery degrees (MB.BS) from the University of Newcastle Upon Tyne and is a Member of the Royal College of Physicians (MRCP) and a Member of the Faculty of Pharmaceutical Medicine (MFPM). Who is The FDA Group? The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus in Quality Assurance, Regulatory Affairs, and Clinical Operations. https://www.thefdagroup.com/

In this episode of Life Science Success, my guest is Dr. Helen Torley.  Dr. Torley is the President and CEO of Halozyme. Halozyme's innovative and disruptive solutions provide new therapeutic options that could significantly improve the patient experience by changing how treatments are delivered.  Dr. Helen Torley, CEO of Halozyme, discusses the company's dedication to improving patient experiences and outcomes through their research and development of monoclonal antibodies and small molecules. Halozyme places a strong emphasis on corporate culture, including cross-functional collaboration and community outreach. Dr. Torley shares how the book "The Five Dysfunctions of a Team" has influenced her leadership style. Dr. Torley is inspired by the innovative ideas and enthusiasm of her team members. She expresses concern about the impact of remote work on creativity, problem-solving, and personal development. The company is focused on putting patients at the center of their mission. They have a strong focus on community outreach, with 70% employee participation in volunteering events. She shares a personal story about a family member's experience with cancer treatment to underscore the importance of improving patient experiences. This episode of the Life Science Success podcast provides insight into the innovative solutions Halozyme is developing and their commitment to patient-centered care.  

Listen on Apple, Google, Spotify, and other platforms. Greg gives an overview of what EXUMA Biotechnology is [02:16] How did Greg get into the biotech industry? [04:26] How did Greg end up in San Diego? [05:18] Greg shares what the biotech community in San Diego was like before [06:29] Greg talks about recycling nature and where that mentality of his comes from [08:16] Greg talks about his first company, Halozyme and working on making recombinant enzymes [09:18] When did Greg realize he wants to do another company? How did he get started? [11:17] Greg talks about CAR-T and where EXUMA is headed [16:50] What's the current state of the FDA for a company like EXUMA? [23:20] Greg shares what people should be looking for from the community and what he's  excited about [24:36] Greg shares his favorite taco spots, Roberto's Taco and Baja [27:59]   Follow Gregory LinkedIn   EXUMA Biotechnology Website | LinkedIn

Hacemos un primera revisión del estado de los mercados. Comentamos resultados de Levi`s y Fastenal. A continuación repasamos el comportamiento en bolsa de empresas como Halozyme therapeutics, SC Pharmaceuticals, Richardson electronics y Harrow Health. Terminamos dando un pequeño repaso a dos empresas que reparten un buen dividendo

Host Dr. John Sweetenham, of the UT Southwestern's Harold C. Simmons Comprehensive Cancer Center, and Dr. Bridgette Thom, of the Memorial Sloan Kettering Cancer Center, discuss a novel intervention to address financial toxicity and social need using the Electronic Medical Record.   TRANSCRIPT Dr. John Sweetenham: Hello. I'm Dr. John Sweetenham, the associate director for clinical affairs at UT Southwestern Harold C. Simmons Comprehensive Cancer Center and host of the ASCO Daily News podcast. My guest today is Dr. Bridgette Thom, a researcher at Memorial Sloan Kettering (MSK) Cancer Center. We'll be discussing a novel approach to address financial toxicity that uses the electronic medical record to streamline referrals to financial assistance and counseling for high-risk patients. Our full disclosures are available in the show notes, and disclosures of all guests on the podcast can be found on our transcripts at asco.org/podcasts. Dr. Thom, it's great to have you on the podcast today. Dr. Bridgette Thom: Thanks so much for having me. Dr. John Sweetenham: Dr. Thom, the high costs of cancer care have caused major financial distress for many patients and their families. And this, of course, has been the subject of a great deal of literature in recent years. As you noted in your poster presentation at the recent ASCO Annual Meeting, there are limited interventions, despite a need for patient level and system-based solutions (Abstract 6596). Listeners to our podcast will remember a previous discussion that we had with Dr. Derek Raghavan from the Levine Cancer Institute, where they had instituted financial toxicity grand rounds to partially address this problem. Can you tell us about the novel approach that you and your colleagues explored using the electronic medical record to streamline referrals for financial assistance and counseling? Dr. Bridgette Thom: I first have to credit our team for this work. Dr. Emeline Aviki, who is a gynecological surgical oncologist with keen interest in affordability and payment models, founded the MSK affordability working group several years ago. The first priority of the group was to determine the scope of financial hardship at our institution. At the time, we were absent a systematic screening process. So she, our data analysts, and representatives from our Patient Financial Services Program, developed proxy measures to figure out which patients might be having financial issues. Looking through the medical record, we found those patients who had used one of our Patient Financial Services assistance programs, those who had billing issues, and those who had been referred specifically to social work for a financial issue. And in doing so, we found out that about 25% of our patients over a 2-year period were facing some sort of financial issue. Looking closer at that data, patients experiencing financial hardship weren't necessarily being connected to the resources that we had available, which include copay assistance programs, financial assistance programs, and support for non-medical essential needs. So, for example, we had about 1 in 6 patients who had some sort of payment issue, but only about 20% of them had applied for financial assistance. And we wanted to figure out why this was happening and review the process. In doing so, we discovered that too much burden was being placed on already burdened social workers who had to triage all those issues. So Dr. Aviki in her wisdom realized that care providers, physicians, advanced practice providers (APP), nurses needed to make direct referrals to the resources that we had. So we had a place for patients to go, we just needed an easier mechanism for them to get there. And that was the birth of the financial toxicity order set. And she and her team really powered through the developmental and testing phases working with IT, our strategy administration groups, clinical end users, our PFS team, that's Patient Financial Services. We built this order set that allows clinicians directly to refer to our resources. So clinicians, either through their discussions with patients or if patients bring up an issue, through the order set they can select a reason for a referral, the urgency of referral, the clinical location, etc. And then those orders go directly to our Patient Financial Services staff who then contact patients. We piloted this program in late 2020, early 2021 on 1 service, and then used that feedback to roll out the program first to our outpatient clinics and then to inpatient. That process involved a lot of educational efforts, getting the word out, and working with IT and our strategy team to stay on top of the data and monitor referrals over time. Dr. John Sweetenham: Thanks. Could you say just a little bit more about the educational process that you use? I noticed in looking at your poster that the bulk of referrals came either from the clinic nurse or from the APP. Did you tailor your education in any way to the specific provider that was involved? How did you do that piece? Dr. Bridgette Thom: Our affordability working group is an interdisciplinary team and we have nurses, social workers, physicians. So we did a lot of grand rounds work tailored to the audience be it by disease type or clinical role. Dr. John Sweetenham: Great, thank you. This is clearly great work. There's a lot of useful and helpful information in your abstract and in your poster. What would you say are the key takeaways from the intervention? What would you say about the scalability of this approach into community practice as opposed to a very large institution such as yours? Dr. Bridgette Thom: One key takeaway from a process perspective was the need, like I said, for an interdisciplinary approach to handling the issues. That might seem obvious, but it was really crucial to the success of the project to engage key departmental stakeholders and decision makers very early in the process and keep them informed throughout the development of the order set. That definitely helped us to smooth a potentially bumpy road when we're dealing with big systems change. From an outcomes perspective, a key takeaway is the importance of having actionable items to empower the care providers. So while our institution has this amazing program, our Patient Financial Services program which provides counseling, and connects patients to tangible resources, this type of intervention I think could be scalable or applicable to a community practice or smaller hospital, provided there's somebody, a social worker, patient navigator, [or] nurse, that can be a connection for patients and those potential resources that do exist out there. For us going forward, we're going to continue to evaluate the order set, both from the clinical end user and then also the Patient Financial Services staff to learn more about their perspectives and what can be adapted in the order. We also, of course, want to learn from our patients about their experience with the process, and so we have projects, both research and program evaluation, in the works to consider their perspective. Dr. John Sweetenham: Great, thank you. And I guess 1 of the other aspects of this where there is obviously substantial opportunity is that, of course, currently, you're still reliant upon the provider to place the order. And I wonder whether you feel that some form of screening for social need and financial hardship could be embedded within the electronic health record as a key next step, so that you proactively identify those high-risk patients. Dr. Bridgette Thom: Definitely. And that is, in fact, our next step. We are currently piloting our financial hardship screening tool on 4 large services at our institution. The objective here is to, like you said, proactively identify patients who might be at risk and connect them to resources, be it tangible resources, or just counseling or insurance guidance, [and] do that before the hardship can occur. And the goals of our pilot phase are to (1) develop and refine a tool that's both predictive, but also feasible to administer within a busy clinic setting. And then also (2) to work with our interdisciplinary team to adapt the workflow. We can have a great tool, but if we don't have a way to administer it in a clinic, it's not going to do us any good. So for us, that means listening to feedback from, first and foremost, our patients and then the key stakeholders in the process. Our nurses have been integral to this process. We also, of course, our Patient Financial Services, staff, the clinical operations staff, obviously, IT, social work. And once we have these processes figured out and we have our tool solid, we will hopefully expand the screening to all services, and then use data to figure out the optimal screening interviews by disease and treatment type because we feel that this could vary by a patient's treatment trajectory. Dr. John Sweetenham: You note in your poster that additional multilevel interventions are needed to address the problem of financial toxicity at a systems level, and of course, what you have done here is a really great and important step in helping to identify those patients. But identifying those patients who are at particular risk is only beginning of addressing the issue. Could you elaborate a little bit more on other areas that you're exploring in terms of the interventions that you're using? Dr. Bridgette Thom: Sure. And this idea of multi-level interventions comes from my social work training, where there's an emphasis on viewing the individual as being part of a series of dynamic and interconnected relationships and systems: the social ecological theory. So if we think of concentric circles with the patient at the center, there are cascading relationships that are going to impact the course of their care. We radiate out to families and caregivers, a patient's workplace if they're employed, the hospital and the providers there, and then look to bigger systems where a patient lives, their town. If it's in an urban setting or a rural setting, the type of insurance that they have, if it comes from their employer, or if it's a different insurance system, their community and then of course, broader, social, societal, more macro issues. My point and that of many others who work in this space is that we have to consider the context. We can't just build and test interventions that focus on a patient because the patient isn't existing in a bubble. They're existing in relationships with their caregivers, their health care providers, their health care system. And all of that exists in, for lack of a better word, a broken system of structural inequality, systemic racism, and conflicting values about health care as a right. Patient-level interventions are indeed important, but we can't place the burden solely on the patient. And we, as researchers and clinicians in this space, really need solutions that are going to reach across systems. I think, like you said, this project demonstrates that and this is something that I hear from patients in other work that I'm doing. For example, I'm working on a digital intervention to help young adult cancer survivors to build their financial capability and build their understanding of the health care system and insurance systems and financing and all of that. As I co-develop this intervention with patients and survivors, I'm hearing, 'This is great. I'm glad I'm learning these things, but at the same time, my co-pays are unmanageable,' Or, 'I might have to skip my survivorship appointment because I can't afford to take off work that day.' I think we have to really think about, like I said, the context and the bigger picture of the scope of the problem and build and develop interventions that acknowledge that. Dr. John Sweetenham: Well, as you say, very complex, multi-level problem and many interventions needed. But congratulations and kudos to you and your colleagues for addressing one component of this. And we're really looking forward to seeing how this develops and progresses in the coming years. And I'd like to thank you, again, for sharing your insights with us today on the ASCO Daily News podcast and telling us a little bit more about this great work. Dr. Bridgette Thom: Thank you so much for having me. I want to just acknowledge all of the work of our team. It has really been a team effort. We're looking forward to our next steps. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the poster discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. You can hear more about the MSK Affordability Working Group's efforts on the podcast, Cancer Straight Talk from MSK.   Disclosures: Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness Dr. Bridgette Thom: Stock and Other Ownership Interests (Immediate Family Member): Caladrius Biosciences, Mediwound, Sierra Oncology, Lipocine, MEI Pharma, Oncternal Therapeutics, Avadel Pharmaceuticals, Chimerix, Avidity Biosciences, Sutro Biopharma, Adma Pharma, Concert Pharmaceuticals, Processa Pharmaceuticals, Curis           An, IMV, Arcus Biosciences, Iovance Biotherapeutics, Qiagen, Revance Therapeutics, DermTech, Zimmer BioMet, Axonics Modulation, Halozyme, Autolus, Pavmed Inc       , Mereo BioPharma, and AADi Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

Mr. Gergen was appointed Chief Executive Officer of Poseida in February 2022. He joined Poseida in February 2018, initially serving as Chief Business Officer and Chief Financial Officer before being named President and Chief Business Officer in July 2020. He has been a member of the Company's board of directors since 2018. Mr. Gergen was previously the Senior Vice President and Chief Operating Officer of Halozyme, Inc. and Executive Vice President and Chief Operating Officer at Mirati Therapeutics, Inc. Previously he served in senior management positions, including as Senior Vice President of Corporate Development, at Amylin Pharmaceuticals, Inc. He also served in senior management positions at CardioNet Inc., Advanced Tissue Sciences, Inc., and Medtronic, Inc. Mr. Gergen received a J.D. from the University of Minnesota Law School and a B.A. in business administration from Minot State University.

Nina Deka, Senior Research Analyst at ROBO Global, rejoins the show to talk about innovations in health care technology and the companies leading the charge. Labor shortages in skilled personnel and inflationary costs are just two reasons the area is ripe for disruption with automation and digitization. Then there are breakthroughs in treatments and therapies from liquid biopsy to synthetic biology that are elevating the importance of precision medicine. For the video version, visit investors.com/podcast.

Matt Caruso, President of Caruso Insights, rejoins the show to talk about using expected returns. Even in looking at market action, it's a good reminder that you can get outsized returns from your individual stocks. But your expected returns need to be high enough in relation to your risk in order to have success. We also take a look at the bull market in oil and gas stocks including Patterson-UTI Energy (PTEN), biotech Halozyme and Box (BOX) in tech. For the video version, visit investors.com/podcast.

The FDA asks for more diversity, $1B for injectors, $2B for a one-trick pony, and $68M to make DNA. Find out more athttps://LifeScienceTodayPodcast.comStory ReferencesFDAAntares + HalozymeGSK + SierraAnsa BiotechnologiesAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry.

About the Episode: How can therapeutics like biologics and small molecule drugs evolve in their delivery? Finn Doyle, SVP and General Manager of ENHANZE® at Halozyme, sits down to discuss exactly how these innovative therapeutics can be delivered subcutaneously where they have previously only been administered via IV, the impacts of doing so, and the keys to successful drug delivery collaborations.  Key Takeaways:  How switching to a SC delivery model impacts patients, healthcare providers and drug development companies Keys to successful partnerships and collaborations How Halozyme's ENHANZE® technology enables the shift from IV to SC About the Speaker: Finn Doyle joined Halozyme in May of 2021 as the Senior Vice President and General Manager of ENHANZE®. She is responsible for overseeing Halozyme's ENHANZE® drug delivery technology, including responsibility for the annual operating plan and long-term growth strategy for the franchise. Ms Doyle will oversee the alliance management, ENHANZE® business development, regulatory and safety, and project management functions within Halozyme. Ms Doyle received a B.S. in Biochemistry from Trinity College in Dublin (Dublin University) and a degree in International Business and Marketing Ireland and did postgraduate research at MIT/Harvard.   For more information: About drug delivery and partnerships, click here.  For more information about PharmaTalk Radio, visit theconferenceforum.org.

In this episode, Philip Agop Philip, MD, PhD, FRCP, and Elena Gabriela Chiorean, MD, discuss the importance of testing for biomarkers along with thecurrent paradigm of PARP inhibitor therapy in the treatment of pancreatic cancer. Topics include:Importance of germline and somatic testingAdverse events associated with PARP inhibitorsMaintenance therapy in pancreatic cancerPresenters:Philip Agop Philip, MD, PhD, FRCPProfessorSchool of MedicineWayne State UniversityLeader, Gastrointestinal Multidisciplinary TeamDepartment of OncologyKarmanos Cancer InstituteDetroit, MichiganElena Gabriela Chiorean, MDProfessor of MedicineDivision of Medical OncologyDepartment of MedicineUniversity of WashingtonMemberFred Hutchinson Cancer ResearchSeattle, WashingtonContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program:https://bit.ly/3jEehCc

The administration of biologics can be challenging because of the sheer volume of product needed to deliver a dose to a patient. It is for this reason that many of these therapies must be infused into a patient, a process that is disruptive, costly, and can take several hours. Halozyme's Enhanze drug delivery technology has been used by a number of biologics producers to take a therapy that would otherwise need to be infused to allow it to be administered with a subcutaneous injection. We spoke to Renee Tannenbaum, vice president of global partnering for Halozyme , about the company's Enhanze drug delivery technology, how it works, and the company's reorganization to focus on partnerships around it.

Ed and reviews his career journey in Information Technology leadership from supporting Quality Control to Sales to Large Pharma to emerging Biotech, Ed developed deep knowledge in the highly sought after expertise in leading in commercializing clinical stage Biotech. He then intentionally chose opportunities that exposed him to all facets of the business so he could engage any leader "around the table". Although Ed has served for many years as a Chief Information Officer (CIO) what he prides himself in the most is his leadership development of those who have reported to him, many of which have now become CIOs themselves. Ed's successful career includes 29 years at Pfizer and tenure at Onyx, MediMune, and Halozyme. Ed Gemo founded Barbosa Consulting focusing on providing IT Strategy Consulting Biotech focused on the Biotechnology / Bio-pharmaceutical industry.https://barbosaconsulting.com/www.titansoftransition.comSupport the show (https://www.buymeacoffee.com/titansot)

As the director of The University of Arizona Cancer Center's Clinical Trials Office, and national expert in pancreatic and biliary cancers, Rachna Shroff, MD, shares the impact COVID-19 has had on our patients, clinical trials, and cancer care. Intro :13 About Dr. Shroff :21 The interview 1:45 How did you end up in GI medical oncology? 1:52 You’ve become a nationally known leader in the biliary space 4:45 How has your clinical practice changed, and how has clinical trial enrollment changed since COVID-19? 6:08 Many clinical trial modifications occurred so quickly; how do you think that was possible? 14:10 What has changed the most for you since COVID-19 began? 10:38 Things have been moving quickly to be more nimble than usual 16:23 Are you concerned about the impact this will have on our patients after the acuity of COVID-19? 17:50 Do you think we’ll see flexibility in treatment plans going forward? 20:42 Do you think clinical trials will be able to incorporate telehealth for check-ins? 22:30 What are your thoughts on how trials/studies/data have been presented about COVID-19 in general? 28:05 How do you help people navigate the data? 31:14 What are you optimistic about for the future? 35:54 How to get in touch with Dr. Shroff 39:23 We’d love to hear from you! Send your comments/questions to oncologyoverdrive@healio.com. Follow us on Twitter @HemOncToday @ShikhaJainMD @rachnatshroff Rachna T. Shroff, MD, MS, is an associate professor in the division of hematology and oncology; chief of the Section of GI Medical Oncology; leader of the GI Disease-Oriented Team; and director of the Clinical Trials Office at The University of Arizona Cancer Center. Disclosures: Jain reports she is a paid freelance writer for Lippincott. Shroff reports she has received research funding from Exelixis, Halozyme, Merck, Pieris and Taiho, and has served as an advisory board member for Agios, Clovis Oncology, Debiopharm, Exelixis, Merck, QED Therapeutics and Seattle Genetics.

Effective drug delivery collaborations combine a wide range of experiences and viewpoints with common goals to achieve successful clinical and regulatory outcomes. But the path to developing this eventual relationship is not without challenges, as partnerships that are not clearly defined upfront or effectively managed downstream can quickly derail the best of intentions. In this podcast, first recorded at the 2019 PODD: Partnership Opportunities in Drug Delivery conference, BMS and Halozyme panelists will shed light on key considerations, challenges and lessons learned during the pre-deal courting process as well as their ongoing successful alliance. Moderated by: Jennifer Guzman, Halozyme Therapeutics Panelists include: Michael Cucolo, BMSBrian Davideit, BMSRenee Tannenbaum, Halozyme TherapeuticsTom Witt, Halozyme Therapeutics To learn more about the 10th annual PODD: Partnership Opportunities in Drug Delivery conference please visit www.theconferenceforum.org

On this week's Tech Nation, part I of a two-part series on Chernobyl: Then and Now. Journalist Adam Higginbotham, author of “Midnight in Chernobyl”, recounts what exactly happened at the time of the accident. Later in the show, Vincent Keunen, the Founder and CEO of Andaman7, describes a new app to collect and manage your own medical records, and Helen Torley of Halozyme returns to talk about a technology which reduces the time for infusion therapy.

On this week’s Tech Nation, part I of a two-part series on Chernobyl: Then and Now. Journalist Adam Higginbotham, author of “Midnight in Chernobyl”, recounts what exactly happened at the time of the accident. Later in the show, Vincent Keunen, the Founder and CEO of Andaman7, describes a new app to collect and manage your own medical records, and Helen Torley of Halozyme returns to talk about a technology which reduces the time for infusion therapy.

On this week’s Tech Nation, part I of a two-part series on Chernobyl: Then and Now. Journalist Adam Higginbotham, author of “Midnight in Chernobyl”, recounts what exactly happened at the time of the accident. Later in the show, Vincent Keunen, the Founder and CEO of Andaman7, describes a new app to collect and manage your own medical records, and Helen Torley of Halozyme returns to talk about a technology which reduces the time for infusion therapy.

On this week’s Tech Nation, part I of a two-part series on Chernobyl: Then and Now. Journalist Adam Higginbotham, author of “Midnight in Chernobyl”, recounts what exactly happened at the time of the accident. Later in the show, Vincent Keunen, the Founder and CEO of Andaman7, describes a new app to collect and manage your own medical records, and Helen Torley of Halozyme returns to talk about a technology which reduces the time for infusion therapy.

On this week’s Tech Nation, part I of a two-part series on Chernobyl: Then and Now. Journalist Adam Higginbotham, author of “Midnight in Chernobyl”, recounts what exactly happened at the time of the accident. Later in the show, Vincent Keunen, the Founder and CEO of Andaman7, describes a new app to collect and manage your own medical records, and Helen Torley of Halozyme returns to talk about a technology which reduces the time for infusion therapy.

On this week’s Tech Nation, Guy Kawasaki, the chief evangelist for Canva, and former chief evangelist of Apple, looks back on his life in “Wise Guy … Lessons from a Life”. Then Pat Condo, CEO of NTENT, describes how our world is changing now that we can speak to the tech around us. Helen Torley, President and CEO of Halozyme, explores how we might fight different aspects of a cancer, making existing cancer treatments more effective. Its first target – pancreatic cancer, with other cancers soon to follow.

On this week’s Tech Nation, Guy Kawasaki, the chief evangelist for Canva, and former chief evangelist of Apple, looks back on his life in “Wise Guy … Lessons from a Life”. Then Pat Condo, CEO of NTENT, describes how our world is changing now that we can speak to the tech around us. Helen Torley, President and CEO of Halozyme, explores how we might fight different aspects of a cancer, making existing cancer treatments more effective. Its first target – pancreatic cancer, with other cancers soon to follow.

On this week’s Tech Nation, Guy Kawasaki, the chief evangelist for Canva, and former chief evangelist of Apple, looks back on his life in “Wise Guy … Lessons from a Life”. Then Pat Condo, CEO of NTENT, describes how our world is changing now that we can speak to the tech around us. Helen Torley, President and CEO of Halozyme, explores how we might fight different aspects of a cancer, making existing cancer treatments more effective. Its first target – pancreatic cancer, with other cancers soon to follow.

Today in FirstWord: